E-Learning

The Dow Jones Industrial Average fell almost 250 points on Tuesday in what could be its longest losing streak since the 1970s.

The grocer, however, will close an underperforming store

Tesla shares hit another record high Tuesday after an analyst upgraded their rating of the electric vehicle maker to above $500.

Commercial quantum computers are years away, but investors may be banking on the idea that they are the future. Here’s what to know.

(Bloomberg) -- UK government borrowing costs rose to the highest level in decades relative to Germany’s, as traders grew increasingly skeptical over how much more easing the Bank of England will manage to deliver next year.Most Read from BloombergHow California Sees the World, and ItselfHong Kong's Expat Party Hub Reshaped by Chinese InfluxLondon’s Tube Fares Are Set to Rise by 4.6% Next YearThe spread between UK and German 10-year bond yields widened to 229 basis points, the highest on a closin

Quantum Computing was awarded a contract by NASA's Goddard Space Flight Center to use its entropy quantum optimization machine to help the space agency's imaging.

The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.

NEW YORK (Reuters) -U.S. stocks followed their European counterparts lower on Tuesday and crude prices fell as investors parsed economic data and girded themselves for a series of central bank decisions, including an expected rate cut from the Federal Reserve. Bitcoin forged new record highs and benchmark U.S. Treasury yields steadied ahead of what is expected to be a "hawkish cut" from the U.S. central bank. "There's profit taking ahead of the Fed meeting," said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut.

You have probably seen warnings that after two years of double-digit gains for the S 500, stocks are getting pricey. Then again, you find warnings that the sky is about to fall down every day in the financial media.

On Tuesday, Biomea Fusion Inc. (NASDAQ:BMEA) revealed topline results from the ongoing COVALENT-111 study of icovamenib in patients with type 2 diabetes (T2D). Icovamenib was investigated in three different dosing arms with a primary follow-up after 26 weeks: Arm A at 100mg QD (once daily) for 8 weeks, Arm B at 100mg QD for 12 weeks, and Arm C at 100 mg QD for 8 weeks and 100mg BID (twice daily) for 4 weeks. Also Read: FDA Removes Clinical Hold On Biomea Fusion’s Early-Stage Trials For Potential